SONAR

Study of Diabetic Nephropathy with Atrasentan

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.

2 648

Schéma

Double-blind RCT, enrichment (responder) design

Critère

Doubling of serum creatinine or ESKD

Pertinence

RésultatHR 0.65 (95% CI 0.49–0.88; p=0.0047); more fluid retention and oedema with atrasentan.

Heerspink HJL, et al. Lancet. 2019;393(10184):1937-1947. 10.1016/S0140-6736(19)30772-X

Discussion et critique

Proof of concept for selective endothelin-A antagonism; the enrichment design limits generalisability.